Michael Hemann

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Kailash29792 (talk | contribs) at 08:20, 24 August 2022 (→‎top: clean up). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Michael Thomas Hemann (born 1971) is an American cancer geneticist and associate professor in the David H. Koch Institute for Integrated Cancer Research at the Massachusetts Institute of Technology. The research in Hemann's laboratory focuses on identification and characterization of genes involved in tumor formation, cancer progression, and chemotherapeutic response.[1][2][3]

Michael Thomas Hemann was born in Evanston, Illinois, in 1971, but grew up in Shaker Heights, Ohio.[4] He attended Wesleyan University for college, eventually graduating with a bachelor’s degree in molecular biology and biochemistry in 1993. He went on to receive his Ph.D. in human genetics from Johns Hopkins University School of Medicine in 2001.[5][6] His thesis work was conducted in Carol Greider's lab.[7][8]

Publications

  • Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT (November 2010). "Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy". Proc Natl Acad Sci U S A. 107 (48): 20786–91. doi:10.1073/pnas.1011409107. PMC 2996428. PMID 21068376.
  • Gilbert LA, Hemann MT (October 2010). "DNA damage-mediated induction of a chemoresistant niche". Cell. 143 (3): 355–66. doi:10.1016/j.cell.2010.09.043. PMC 2972353. PMID 21029859.
  • Doles J, Hemann MT (February 2010). "Nek4 status differentially alters sensitivity to distinct microtubule poisons". Cancer Res. 70 (3): 1033–41. doi:10.1158/0008-5472.CAN-09-2113. PMC 2946156. PMID 20103636.
  • Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT (October 2009). "In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression" (PDF). Nat. Genet. 41 (10): 1133–7. doi:10.1038/ng.451. PMC 2756700. PMID 19783987.
  • Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (August 2009). "The combined status of ATM and p53 link tumor development with therapeutic response". Genes Dev. 23 (16): 1895–909. doi:10.1101/gad.1815309. PMC 2725944. PMID 19608766.

References

  1. ^ "Scientists reveal cancer's hiding spots". Sify. 29 October 2010. Archived from the original on 2 February 2013. Retrieved 19 December 2012.
  2. ^ Hirsch, Jen (8 August 2009). "Genetic Profiling of Tumors Could Have 'Immediate Impact' on Treating Cancer". Medical News Today. Retrieved 19 December 2012.
  3. ^ "Cancer cells may be protected post-chemo". UPI. 1 November 2010. Retrieved 19 December 2012.
  4. ^ "Precision attack on cancer". MIT News | Massachusetts Institute of Technology. Retrieved 2020-11-02.
  5. ^ "The Koch Institute: Michael Hemann". ki.mit.edu. Retrieved 2020-11-02.
  6. ^ "Precision attack on cancer". MIT News | Massachusetts Institute of Technology. Retrieved 2020-11-02.
  7. ^ Hemann, M. T. (2000-11-15). "Wild-derived inbred mouse strains have short telomeres". Nucleic Acids Research. 28 (22): 4474–4478. doi:10.1093/nar/28.22.4474. PMC 113886. PMID 11071935.
  8. ^ Hemann, Michael T; Strong, Margaret A; Hao, Ling-Yang; Greider, Carol W (October 2001). "The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability". Cell. 107 (1): 67–77. doi:10.1016/s0092-8674(01)00504-9. ISSN 0092-8674. PMID 11595186.


Stub icon

This article about a geneticist or evolutionary biologist is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Michael_Hemann&oldid=1106374108"